Advancing Gene, Cell, & Tissue-Based Therapies

ARM Annual Report & Sector Year in Review: 2019

The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.

ARM Annual Report & Sector Year in Review: 2019

The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.

Back to Publications

Global Landscape

987+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

534North America22Oceania1Africa180Asia13South America237Europe & Israel

Financings

Total 2019 Global Financings

Total Global Financing

$9.8 Billion

2nd Highest Year on Record

Gene & Gene-modified
Cell Therapy

$7.6 Billion

2nd Highest Year on Record

Cell Therapy

$5.1 Billion

4th Highest Year on Record

Tissue Engineering

$442 Million

3rd Highest Year on Record

Total Global Financings by Type

25439951084155768519274715157831161238562243814934108876IPOsFollow-OnsCorporatePartnershipsVenture CapitalPrivatePlacement /PIPES0$500m$1,000m$1,500m$2,000m$2,500m$3,000m$3,500m$4,000m$4,500m$5,000m$5,500m$6,000m201720182019
135421894411280Mergers &Acquisitions0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m$18,000m$20,000m$22,000m$24,000m201720182019
1,066

regenerative medicine
clinical trials ongoing worldwide
as of the end of 2019

35.7%55.4%8.8%050100150200250300350400450500550600Phase 1Phase 2Phase 3

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

EOY 2019

Gene Therapy
31.5%59.4%9.1%020406080100120140160180200220Phase IPhase IIPhase III
Gene-Modified Cell Therapy
& Cell-Based IO
49.1%47.6%0020406080100120140160180200220240Phase IPhase IIPhase III
Cell Therapy
19.4%66.7%13.9%02030405060708090100110120130140150Phase IPhase IIPhase III
Tissue Engineering
13.0%50.0%37.0%0681012141618202224Phase IPhase IIPhase III

Clinical Trials by Indication: 2019

Oncology
657
Musculoskeletal
60
Central Nervous System
57
Endocrine, Metabolic, and Genetic Disorders
55
Cardiovascular
46
Hematology
35
Ophthalmology
33
Immunology & Inflammation
31
Dermatology
23
Infectious Diseases
21
Genitourinary Disorders
16
Gastroenterology
16
Respiratory
10
Geriatric Diseases
3
Lymphatic Disease
2
Surgery
1
Ear Diseases
1

Report Infographics

View European Data View Full Report

Alliance for Regenerative Medicine

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

2-4 Schuman Roundabout
B-1040 Brussels
Belgium